Soligenix (NASDAQ: SNGX) reported 2025 results highlighting progress across its rare disease pipeline, including advancing its Phase 3 FLASH2 trial of HyBryte(TM) for cutaneous T-cell lymphoma with interim analysis expected in Q2 2026 and top-line results anticipated in the second half of the year. The company also noted regulatory momentum with orphan drug designation for dusquetide in Behcet’s Disease, ongoing development of SGX302 and SGX945 programs and a year-end cash position of approximately $7.9 million, as it continues to pursue strategic options to support late-stage development.
